Both machines abrade the skin inside a film of fluid and suck the debris away. SilkPeel's distinguishing claim is that it drives a serum into the skin at the same time, under pressure. That claim has a name, dermalinfusion, and it is the whole reason the device exists as a separate product. Everything else the two machines do is close enough that most people would not be able to tell them apart during the appointment.
The claim to examine is not whether a serum is applied. It is whether it goes deeper than it otherwise would. A serum spread on skin by hand mostly sits on the surface. The idea behind infusion is that abrading the top layer first, then pushing fluid against it under a sealed vacuum head, gets more of the active ingredient past the barrier. That is a physically reasonable idea. It is also one that has never been measured for this device.
A search of the medical literature for SilkPeel returns nothing at all. Not a small study, not a weak study. Zero indexed papers. Searching for dermalinfusion returns one paper about the device, a 2014 report on a peptide for dark patches left behind after inflammation in darker skin, and even that record carries no abstract and no author affiliations, so its size and its funding cannot be established. HydraFacial has three papers, all small. Neither device has ever been tested against the other.
Neither device is FDA-cleared, because the category is exempt from FDA review. SilkPeel, its later names Dermalinfusion and DiamondGlow, and HydraFacial are all registered as Class I devices under product code GFE, "powered dermabrasion brush," 21 CFR 878.4820, which is 510(k) exempt. There is no clearance number for either and no FDA-reviewed use. That does not make them unsafe or unregulated. Registration, product listing, manufacturing quality rules and the ban on false labeling all still apply. It means the FDA has never assessed the infusion claim, or any other claim, for either machine.
Originally made by Envy Medical, bought by Allergan in March 2019 and now under AbbVie. Sold over time as SilkPeel, SilkPeel Pro, Dermalinfusion and, after a rebrand under the SkinMedica name, DiamondGlow. A medical-grade diamond treatment tip abrades the surface while the handpiece is sealed against the skin by vacuum, and serum is fed to the same head so it meets freshly abraded skin under pressure. The manufacturer's own description is that it exfoliates, extracts and infuses in one motion.
Made by Edge Systems, now HydraFacial LLC, under The Beauty Health Company. A disposable spiral-channel tip makes the fluid swirl while vacuum pulls it, and the loosened debris, away into a waste jar. The company calls this Vortex-Fusion. Some kits also use a wet diamond pad, in 100 or 120 grit.
No study has measured how far any ingredient travels into skin after a SilkPeel or DiamondGlow treatment, at what concentration, or for how long. The infusion claim rests on the design of the handpiece and on general principles, not on a measurement.
No penetration study exists for HydraFacial either. Its serums are applied through the same tip that abrades, so the same reasoning and the same absence of data apply.
The current owner states plainly that its infusion serums are intended to meet the FDA's definition of a cosmetic product and are not intended to be drugs that diagnose, treat, cure or prevent any disease. It also describes the machine itself as a general dermabrasion device and does not claim FDA clearance for it.
Base solutions contain glycolic and salicylic acid at low concentration, according to the manufacturer's own account in an FDA report. Add-on boosters are sold separately under names such as HydraFillic with Pep9, ReGen GF+ and HydraLock HA.
No 510(k) exists for SilkPeel, Dermalinfusion, DiamondGlow or Envy Medical. Class I, GFE, exempt. General controls apply; premarket review does not.
Same exempt classification. Edge Systems holds three clearances in total, for sterile tubing and for blue and red LED light modules, and none of them covers the abrading and infusing engine.
SilkPeel returns no records at all in the medical literature. The one device paper indexed under dermalinfusion, from 2014, looked at a peptide for dark patches in skin of color, and its record carries no abstract and no affiliations, so its size and funding are unknown. A 2024 study of 29 women used the DiamondGlow machine with a growth-factor serum for 12 weeks, but participants also used a serum twice daily at home for those 12 weeks, and the authors worked for the manufacturer. That design cannot separate the machine from the home product.
A randomized 2008 study of 20 women found changes on biopsy after six hydradermabrasion treatments with a serum, while the same serum applied by hand produced none. A 2022 open-label acne study of 20 adults, with a company employee among the authors, found the share rated clear or almost clear rose from 20 to 65 percent by investigator rating. An independent imaging study of 8 volunteers found no visible collagen change at two weeks.
The manufacturer lists a scratchy, stinging feeling during treatment and temporary tightness, redness or slight swelling afterwards, with severe irritation and allergic reactions as uncommon. Two reports were filed with the FDA in February 2025. One describes inflamed red stroke marks along the path of the tip, on the neck and under one eye, which settled within an hour after an antihistamine. The other describes an allergic reaction that began at the jawline and spread to the neck, face and eyes, which the manufacturer later assessed as not device-related. Both are single voluntary reports, and neither establishes a rate.
Redness and tightness for a few hours is the usual account. Two adverse event reports exist for HydraFacial in the FDA's public database in roughly fifteen years, one of redness and a breakout the next day, one of acidic fluid reaching the eyes when they were not shielded.
No professional society and no manufacturer publishes a price for this treatment. Clinic menus are the only source, and they are commercially interested, so no dependable figure exists.
RealSelf reported an average of $209 from 261 consumer-submitted reviews, with prices up to $320, last updated 13 July 2023. Self-reported, US-only and now several years old.
Abrading the surface first does increase how much gets through. That part is well established in skin science generally. What has never been shown is that these machines do it in a way that matters for a cosmetic ingredient.
Three separate things get run together in the sales pitch, and they are worth pulling apart.
The first is that removing part of the outer layer lets more through. That is true, and it has been measured for other mechanical methods. In one split-face study of 30 women with Fitzpatrick skin types IV and V, passing a microdermabrasion handpiece over one side before applying a glycolic acid peel to the whole face produced a significantly larger drop in pigment score on the pre-treated side. The margin was small and the finding was single. But it is the kind of evidence the infusion claim needs, and notice that it is about a peel agent, not a cosmetic serum, and it was not done with either machine here.
The second is that suction helps. The best support is that split-face study of 23 women where a mild acid with negative pressure beat the same acid alone on blackheads and whiteheads. Again: research setup, not a branded device.
The third is the part with nothing behind it, which is the specific claim that pressure at the handpiece drives a particular branded serum to a particular depth. No one has measured how far anything travels, how much arrives, or how long it stays there, in a SilkPeel, a DiamondGlow or a HydraFacial. The literature on the whole hydradermabrasion technology is five papers, and none of them is a penetration study.
So the honest position is that the mechanism is plausible and partly supported by work on other devices, and the product-specific claim is untested.
The one thing that has been measured is how much surface layer comes off. Using a high-resolution imaging technique on 8 volunteers with skin types II to V, average stratum corneum thickness went from 9.42 micrometers before treatment to 6.67 micrometers straight after, and was back to 9.75 micrometers two weeks later. So a little under 3 micrometers came off, and the layer regrew slightly thicker than it started.
That study also looked for collagen change at two weeks and found none: no visible difference in the quality or quantity of collagen fibers. It did not name the brand of machine, so the finding sits equally on both lanes.
This is useful context for the infusion argument. The window in which the barrier is thinner is small, and it closes.
SilkPeel has been renamed twice and changed owners twice. Envy Medical made it, Allergan bought the company in March 2019, and the same physical machine now sells as DiamondGlow under the SkinMedica name within AbbVie. Second-hand listings for the machine still carry all three names in one line.
This matters when you are comparing prices or reading reviews, because you may be reading about the same device three times under different labels and thinking you have found three sources.
Tell your provider if you get cold sores. Antiviral medicine is started before the appointment, so it has to be prescribed in advance.
Say what you are already using at home. Retinoids, prescription acne treatments and strong acids all thin the surface layer, and a treatment that thins it further can tip into irritation.
Ask which serum is going on your skin and to see the ingredient list, particularly if you have ever reacted to a skincare product. Two reactions to this device family sit in the FDA's public database, and neither is a straightforward injury from the abrasion itself: a 2025 report of an allergic reaction to a serum, which the manufacturer later closed as not device-related, and a 2025 report of inflamed red marks along the path of the tip that had settled within an hour. The one accepted device-associated injury in this family remains acidic fluid reaching a patient's eyes when they were not shielded, so ask about eye protection. The manufacturer's own instruction is not to treat skin whose quality is already compromised.
If your skin is deeper in tone, say so and ask the operator to keep the suction and the abrasion gentle. Any irritation in richly pigmented skin can leave post-inflammatory hyperpigmentation — dark patches that stay behind after the skin is inflamed. There is no published safety data for this treatment specific to darker skin tones, and the single consumer report of lasting color change in FDA's database came from a patient with dark skin, so this is caution rather than a measured risk.